Equities analysts forecast that CareDx, Inc. (NASDAQ:CDNA) will post earnings of ($0.13) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for CareDx’s earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.15). CareDx also posted earnings of ($0.13) per share in the same quarter last year. The company is scheduled to report its next earnings report on Friday, April 20th.

Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow CareDx.

CareDx (NASDAQ:CDNA) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. The business had revenue of $12.19 million during the quarter, compared to the consensus estimate of $12.05 million. CareDx had a negative return on equity of 157.00% and a negative net margin of 84.14%. The company’s quarterly revenue was down 2.3% compared to the same quarter last year.

A number of research firms recently commented on CDNA. HC Wainwright began coverage on CareDx in a report on Monday, November 27th. They issued a “buy” rating and a $12.00 price objective for the company. Craig Hallum reiterated a “buy” rating and issued a $10.00 price objective (up previously from $4.00) on shares of CareDx in a report on Monday, October 9th. Raymond James Financial upgraded CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price objective for the company in a report on Wednesday, September 27th. ValuEngine upgraded CareDx from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $7.00 price objective (up previously from $3.00) on shares of CareDx in a report on Tuesday, September 26th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. CareDx presently has a consensus rating of “Buy” and an average target price of $7.75.

CareDx (NASDAQ CDNA) traded down $0.14 during midday trading on Thursday, reaching $7.12. The company had a trading volume of 214,572 shares, compared to its average volume of 367,689. The company has a quick ratio of 0.35, a current ratio of 0.55 and a debt-to-equity ratio of -124.53. CareDx has a fifty-two week low of $0.76 and a fifty-two week high of $7.98.

In other CareDx news, COO Mitchell J. Nelles sold 10,948 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $7.17, for a total value of $78,497.16. Following the completion of the transaction, the chief operating officer now directly owns 84,225 shares of the company’s stock, valued at $603,893.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Neil Gagnon bought 10,642 shares of the firm’s stock in a transaction on Thursday, October 5th. The stock was acquired at an average cost of $4.00 per share, with a total value of $42,568.00. The disclosure for this purchase can be found here. 5.40% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of CDNA. Royce & Associates LP grew its stake in CareDx by 39.3% in the second quarter. Royce & Associates LP now owns 733,287 shares of the company’s stock valued at $814,000 after acquiring an additional 206,815 shares during the period. Stonepine Capital Management LLC acquired a new position in CareDx in the second quarter valued at about $212,000. Trellus Management Company LLC acquired a new position in CareDx in the third quarter valued at about $100,000. Thompson Davis & CO. Inc. grew its stake in CareDx by 3,294.9% in the third quarter. Thompson Davis & CO. Inc. now owns 203,692 shares of the company’s stock valued at $754,000 after acquiring an additional 197,692 shares during the period. Finally, Perkins Capital Management Inc. acquired a new position in CareDx in the third quarter valued at about $513,000. 23.15% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/03/0-13-eps-expected-for-caredx-inc-cdna-this-quarter.html.

CareDx Company Profile

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Get a free copy of the Zacks research report on CareDx (CDNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related stocks with our FREE daily email newsletter.